Proceedings · Session S-447 · filed November 19, 2026

Lab Technology & MethodsSession paper

Anemocyte wins CPHI 2026 award for one-pot GMP mRNA method

Anemocyte’s one-pot AMCAP won a 2026 CPHI manufacturing award after a GMP-first redesign that excludes animal-derived inputs and supports milligram-scale vaccine batches.

By Rebecca Stone4 min read738 words

Summary

  • Anemocyte won the CPHI Award for Manufacturing Excellence at CPHI Milan in October 2026 for AMCAP, a one-pot mRNA synthesis technology.
  • AMCAP was developed in R&D with GMP-compatible, animal-free materials selected from the outset.
  • The design draws on more than 25 years of Anemocyte experience in GMP manufacturing for biologics and advanced therapy products.
  • Personalized immuno-oncology and rare-disease vaccines require milligrams of mRNA rather than grams or kilograms.
  • Pupo says running 1 reaction instead of 2 or 3 shortens processing while retaining segregation in closed systems.
<![CDATA[Transitioning mRNA from R&D to GMP]]>
Figure<![CDATA[Transitioning mRNA from R&D to GMP]]> — torstensimon / pixabay

By Rebecca Stone

Anemocyte won the CPHI Award for Manufacturing Excellence at CPHI Milan in October 2026 for AMCAP, its one-pot technology for messenger RNA (mRNA) synthesis. The award recognizes a manufacturing method, not clinical efficacy: the source interview provides no trial results for vaccines made with AMCAP.

Marco Pupo, PhD, innovation and development coordinator at Anemocyte, described the move from research and development to good manufacturing practice (GMP) production and the facilities required for it. Anemocyte is a biotech manufacturing organization specializing in contract development and manufacturing of plasmids.

Why did AMCAP begin with GMP inputs?

Anemocyte developed AMCAP in R&D but designed it for GMP production from the outset. Pupo linked that choice to Anemocyte’s more than 25 years of GMP manufacturing experience in biologics and advanced therapy products. Designing to manufacturing standards at the research stage narrows the later transfer from development material to regulated production material.

Technologies built around research-grade enzymes formulated with BSA (bovine serum albumin), glycerol or other animal-derived components proved difficult to translate into GMP. The AMCAP team therefore used GMP-grade, animal-free materials throughout development, rather than waiting to replace research-grade inputs after scale-up.

What must suppliers provide?

Pupo suggested that proprietary enzymes, plasmids and NTPs (nucleoside triphosphates) come from suppliers able to provide regulatory starting materials, supporting documentation and validated analytical release testing. He cited BSE/TSE (bovine spongiform encephalopathy and transmissible spongiform encephalopathy) statements as examples of the documentation needed to establish material provenance.

Supplier quality also affects consistency. Pupo advised companies to adopt GMP-grade enzymes from the beginning because those enzymes undergo stringent lot-to-lot activity assays and show less batch variability than research-grade material. No assay results or variability ranges appear in the source, so the comparison remains a process claim rather than a published performance benchmark.

Pupo also called for close work with contract development and manufacturing companies that supply raw material. Meeting sterile drug-product expectations for endotoxin, bioburden and elemental impurities depends on that supply chain, which makes supplier qualification a release and facility-design issue as well as a purchasing task.

Why are facilities moving toward smaller, modular production?

Pupo said: “The pandemic-era mega-batch model is no longer the driver.” Personalized vaccines targeting immuno-oncology indications and rare diseases require milligrams of mRNA rather than grams or kilograms. For facility planners, this shifts the design from scale-up to scale-down, away from large, fixed plants toward speed, modularity and a small footprint.

Turnaround time has clinical value. Pupo also said: “Running 1 reaction instead of 2 or 3 shortens the process while maintaining segregation in closed systems.” The source provides no reaction-time or cycle-time measurements, so the operational advantage remains unquantified.

Can milligram batches be economical?

Small batches carry high fixed costs, according to Pupo, so minimizing consumption of cap analogs (reagents that add the cap structure to messenger RNA) and enzymes is what makes personalized batches financially sustainable and, ultimately, deliverable to patients in time. That is the economic mechanism behind the proposed shift: control input and reaction consumption while reducing the fixed-capacity burden.

The source provides no published cost comparison. It gives no per-dose cost, minimum batch size, enzyme-consumption rate, cap-analog consumption rate or reaction yield. R&D managers therefore need those values before treating modular scale-down as a budgeted manufacturing option rather than a design preference.

What has actually been demonstrated?

The interview documents an award, a development philosophy and a facility proposal, not independent process validation. It gives no sample sizes for analytical testing, no batch yields, no validated impurity thresholds, no cycle times and no comparative cost data. It also does not identify a funder for AMCAP.

Anemocyte’s 25-year GMP history in biologics and advanced therapy products provides relevant experience, but the interview does not show that performance in those areas has been reproduced with AMCAP. The CPHI award recognizes manufacturing excellence for the one-pot technology; it does not, in the material provided, establish product release specifications or clinical performance.

The next checkpoint for R&D managers is supplier-level evidence: GMP-grade animal-free inputs, documented starting-material controls, validated release testing and measured economics for milligram-scale batches. If AMCAP-like performance survives outside development campaigns, scale-down can become a manufacturing strategy rather than a response to smaller individual doses.

via pharmtech.com (Source)

Filed under

  • mrna-manufacturing
  • gmp-production
  • one-pot-synthesis
  • modular-biomanufacturing
  • supplier-qualification
Share this article:

More from Rebecca Stone

Rebecca Stone

Show full bio

Market editor covering regulation, policy and their impact on research and development at Hypothesis Wire.

278 articles

References

  1. WHO's 15-Partner mRNA Programme Tests the Industry's Manufacturing Playbook
  2. AMCAP one-pot mRNA process wins CPHI manufacturing award
  3. AbbVie, Takeda Join Ginkgo-Apheris Antibody Developability Push
  4. S2N.Bio starts Alzheimer's cell therapy tech transfer in Melbourne
  5. Evox Builds Potency Assay for Extracellular Vesicle Pipeline

« Previous articleNext article »